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Abstract 
Background: The addition of bevacizumab to temozolomide-based 
chemoradiotherapy (TMZ/RT→TMZ) did not prolong overall survival (OS) in patients 
with newly diagnosed glioblastoma in phase III trials. Elderly and frail patients are 
underrepresented in clinical trials, but early reports suggested preferential benefit in 
this population.  
Patients and Methods: ARTE was a 2:1 randomized, multi-center, open-label, non-
comparative phase II trial of hypofractionated RT (40 Gy in 15 fractions) with 
bevacizumab (10 mg/kg x 14 days) (arm A, N=50) or without bevacizumab (arm B, 
N=25) in patients with newly diagnosed glioblastoma aged >65 years. The primary 
objective was to obtain evidence for prolongation of median OS by the addition of 
bevacizumab to RT. Response was assessed by RANO criteria. Quality of life (QoL) 
was monitored by the EORTC QLQ-C30/BN20 modules. Exploratory studies included 
molecular subtyping by 450k whole methylome and gene expression analyses. 
Results: Median PFS was longer in arm A than in arm B (7.6 and 4.8 months, 
P=0.003), but OS was similar (12.1 and 12.2 months, P=0.77). Clinical deterioration 
was delayed and more patients came off steroids in arm A. Prolonged PFS in arm A 
was confined to tumors with the receptor tyrosine kinase (RTK) I methylation subtype 
(HR 0.25, P=0.014) and proneural gene expression (HR 0.29, P=0.025). In a Cox 
model of OS controlling for established prognostic factors, associations with more 
favorable outcome were identified for age <70 years (HR 0.52, P=0.018) and 
Karnofsky performance score (KPS) 90-100% (HR 0.51, P=0.026). Including 
molecular subtypes into that model identified an association of the RTK II gene 
methylation subtype with inferior OS (HR 1.73, P=0.076).  
Conclusion: Efficacy outcomes and exploratory analyses of ARTE do not support the 
hypothesis that the addition of bevacizumab to RT generally prolongs survival in 
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elderly glioblastoma patients. Molecular biomarkers may identify patients with 
preferential benefit from bevacizumab. 
 
Clinical trial registration number: NCT01443676 
 
 
Key message 
The randomized, open-label, phase II ARTE trial explored the efficacy of 
bevacizumab in combination with hypofractionated radiotherapy in patients with 
newly diagnosed glioblastoma aged >65 years. Median progression-free survival was 
2.8 months longer in the bevacizumab arm, but overall survival was similar. The 
notion of preferential benefit from bevacizumab in elderly patients was not confirmed.
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Introduction 
 
Almost 50% of all patients with glioblastoma are older than 65 years, less than 20% 
of these survive the first year [1]. Many elderly patients with glioblastoma are deemed 
too frail to tolerate combined post-operative temozolomide chemoradiotherapy 
(TMZ/RT→TMZ), [2, 3] rendering monotherapy regimens of hypofractionated RT [4] 
or TMZ alone preferred treatment options for some of these patients [5-7]. 
The vascular endothelial growth factor (VEGF)-targeting antibody bevacizumab 
(AvastinTM) was considered an optimal candidate drug to improve overall survival 
(OS) of elderly glioblastoma patients based on results of early, uncontrolled clinical 
reports that suggested preferential benefit from bevacizumab in frail and elderly 
patients (Note S1). Yet, bevacizumab failed to prolong overall survival (OS) in two 
phase III trials and there was only a trend for more benefit from bevacizumab in 
patients with unfavorable prognostic factors, although frail elderly patients were 
underrepresented in these trials since being eligible for TMZ/RT→TMZ was an 
inclusion criterion in both trials [8, 9]. 
 
 
Patients and Methods 
 
Study design 
ARTE (NCT01443676) was designed as a 2-arm, randomized, non-comparative, 
open-label phase II trial. The primary objective was to determine the efficacy and 
tolerability of the combination of bevacizumab and radiotherapy in elderly patients 
with newly diagnosed glioblastoma. The primary endpoint was median OS. Major 
inclusion criteria were: age 65 years or older, newly diagnosed supratentorial 
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glioblastoma, eligible for first infusion of bevacizumab > 28 and < 49 days after 
surgery for glioblastoma, Karnofsky performance score (KPS) of 60 or more, stable 
or decreasing corticosteroid dose within 5 days prior to enrolment, availability of 
paraffin-embedded tissue for central pathology review and determination of O6-
methylguanine DNA methyltransferase (MGMT) promoter methylation status, and 
adequate hematological, renal and liver function. An amendment (11/2013) 
requested the absence of MGMT promoter methylation when it became clear that 
MGMT promoter methylation predicted larger benefit from temozolomide alone than 
from RT alone in patients with glioblastoma aged >65 years [5, 6]. All patients gave 
written informed consent, and the study was approved by the local ethical 
committees and competent authorities (KEK-ZH No. 2011-0135).  
 
Central pathology review and molecular analyses 
Histological diagnoses were reviewed centrally (E.R.) based on the 2007 World 
Health Organization (WHO) classification [10]. Molecular assessments included IDH 
mutation, MGMT promoter methylation, genome-wide CpG methylation and nCounter 
gene expression arrays (Note S2). 
 
Study treatment, assessments and endpoints 
Patients were allocated to treatment arms using a web-based randomization system 
without stratification in a 2:1 distribution. RT was administered to the gross tumor 
volume plus a 2 cm margin over 3 weeks, in 15 fractions of 2.66 Gy, to a total 40.0 
Gy. Bevacizumab was administered intravenously at 10 mg/kg bodyweight every two 
weeks. Dose delays were foreseen for adverse reactions associated with 
bevacizumab that were considered likely to evolve into serious or life-threatening 
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events. Bevacizumab was stopped for disease progression or unacceptable toxicity, 
including life-threatening events or subjective patient-related factors. Details on 
clinical assessments and endpoints are provided in Note S3. 
 
Statistical analyses 
The initial sample size was 40 patients for arm A and 20 patients for arm B. Sample 
size calculations were based on the experimental arm only for the null hypothesis 
that, based on NOA-08 [6], median OS was 10 months, for an approximate 80% 
power to detect an improvement of 2 months using a two-sided alpha level of 10%. 
Per amendment, the study design was modified to aim for enrollment of 60 patients 
with tumors without MGMT promoter methylation. Details on the applied statistical 
tests are summarized in Note S4.  
 
 
Results 
 
Patient characteristics 
At 9 sites in Switzerland, 75 patients aged 65 years or older were randomized from 
3/2013 to 8/2015 (Figure S1). Arms A and B were overall well balanced (Table 1). 
More patients in arm A had cognitive impairment (42% versus 15%, P=0.032). The 
MGMT promoter methylation status was available for 72 patients (96%), 55 tumors 
(76%) had an unmethylated MGMT promoter. Genome-wide methylation arrays 
revealed 16 tumors (28%) with receptor tyrosine kinase (RTK) I, 23 tumors (40%) 
with RTK II and 16 tumors (28%) with mesenchymal (MES) methylation patterns. 
Gene expression subtyping revealed 15 proneural (PN) (29%), 19 classical (CL) 
(37%), and 17 MES (33%) glioblastomas. At the time of databank closure (19 August 
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2016), 74 deaths were documented, of which 70 were attributed to tumor 
progression, 1 was of unknown cause, and 3 from pulmonary embolism, myocardial 
infarction and gastrointestinal perforation, respectively. One patient was still on study 
treatment, no patient was lost to follow-up for OS. 
 
Safety and tolerability 
Adverse events are summarized in Table S1. Grade 3-5 events were overall 
infrequent. More adverse events occurred in arm A than in arm B, but there was also 
a longer treatment period in arm A. The rate of thromboembolic events was similar in 
both groups (19% versus 20%), but more severe and life-threatening thromboembolic 
events occurred in arm A (16% versus 8%), including one death each from 
pulmonary embolism and myocardial infarction. Bevacizumab was discontinued for 
reasons other than progression in 4 patients, including death in 1 patient, pulmonary 
embolism in 2 patients and withdrawal of consent in 1 patient. 
 
Efficacy estimates by treatment arm 
The median time from surgery to randomization was 25 days (range 16-41) in arm A 
and 24 days (range 16-37) in arm B (p=0.60). Forty-seven of 50 patients in arm A 
and 23 of 25 patients in arm B completed the intended dose of 40 Gy of 
hypofractionated RT. The median number of bevacizumab administrations in arm A 
was 12 (range 0-86). Median PFS was 7.6 months in arm A and 4.8 months in arm B 
(Figure 1A, Table S2, P=0.003) and PFS at 6 months (PFS6) was 78% and 28% in 
arms A and B (Table S2, P<0.001). Median PFS was also more favorable in arm A 
when analyses were restricted to the per protocol population, i.e., to patients with 
tumors with an unmethylated MGMT promoter and confirmation of the 
histopathological diagnosis by central neuropathology review (Figure S3). Median 
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PFS in the per protocol population was 7.6 months in arm A and 4.7 months in arm B 
(Table S3, P=0.071). Twenty-four of 48 patients in arm A (50%), but 18 of 25 patients 
(72%) in arm B received any salvage therapy at progression (P=0.071). Median OS 
in the intent to treat population was 12.1 months in arm A and 12.2 months in arm B 
(Figure 1B, Table S2, P=0.77), and survival rates at 12 months (OS12) were 54% 
and 56% in arms A and B (Table S2, P=0.85). Similarly, no apparent benefit from 
bevacizumab with respect to OS emerged in the per protocol population (Table S3). 
 
Central radiology review and response assessment  
Serial MRI of 66 patients were available for post-hoc central review. At study entry, 
all but two patients, both from arm A, had contrast-enhancing lesions, which qualified 
for measurable disease. Response measures were balanced between treatment 
arms (P=0.15, Table S4). The locally determined time point of progression was 
centrally confirmed in 54 patients. It was antedated in arm A by 1 scan in 8 patients, 
2 scans in 2 patients and 4 scans in 1 patient, all of which qualified for 
pseudoresponse by RANO criteria because of progression on T2-FLAIR sequences. 
Among patients from arm B, progression was antedated 1 scan in 1 patient. Central 
review confirmed longer PFS in arm A than in arm B (median PFS 7.0 versus 4.7 
months, P=0.029). 
 
Quality of life, cognitive functioning and steroid use 
Adherence of the study population to quality of life measurements at each scheduled 
study visit was in the range of 65-96% in arm A and 44-80% in arm B. Median 
deterioration-free survival from baseline was 5.7 months in arm A and 2.8 months in 
arm B (Figure 1C, Table S3, P<0.001). Prior to progression, no differences were 
detected for individual scales in a generalized linear mixed model, except for less 
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favorable values in arm A for global health (P=0.048) and pain (P=0.027) (Figure 
1D). 
Cognitive functioning was additionally assessed by serial MMSE. It remained stable 
prior to progression in both groups and no difference between arms was detected at 
individual visits (Figure 1E), or in a linear regression model (P=0.43 for differences in 
slopes). Six individuals with a decline in MMSE of 5 points or more prior to 
progression were identified, all of which were treated in arm A. Two of these six 
patients qualified for pseudoresponse by RANO.  
Among 34 patients who were on steroids at study entry, 21 of 22 patients (95%) in 
arm A and 8 of 12 patients (66%) in arm B came off steroids prior to progression 
(P=0.024). The median time on steroids from study entry was 1.6 months in arm A 
and 2.6 months in arm B (P=0.38) (censoring patients at progression). 
 
Exploratory analyses of treatment effects 
Treatment effects on PFS were noted throughout most clinically defined subgroups 
and were pronounced in patients with poor general condition at baseline (KPS <80%, 
HR 0.16, 95% CI 0.06-0.45, P<0.001) and in patients with cognitive impairment at 
baseline (MMSE <27 points, HR 0.08, 95% CI 0.02-0.41, P=0.002). In contrast, no 
improved PFS was noted in patients with better cognitive functioning (MMSE >27, 
HR 0.85, 95% CI 0.42-1.72, P=0.66, Figure S3).  
Exploratory analyses of treatment effects with respect to OS identified no subgroup 
with benefit from bevacizumab, albeit a tendency to prolonged OS was noted in 
patients with poor general condition (KPS 60-80%, HR 0.55, 95% CI 0.24-1.24, 
P=0.15) and patients who did not receive any second line therapy (HR 0.44, 95% CI 
0.17-1.15, P=0.092, Figure S3).  
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Utilizing median PFS or OS as a cut-off, receiver operating characteristics analyses 
failed to identify prognostic cut-offs for baseline planimetric estimates of contrast 
enhancement on T1-weighted images, or for tumor sizes on T2-weighted images, 
including separate analysis of the entire study cohort, arm A or arm B (data not 
shown). 
 
Clinical characteristics and outcome by gene methylation and gene expression  
Unsupervised clustering of gene methylation similarities reflected the methylation 
classifier-based assignment of glioblastoma subtypes (Figure 2A). Groups defined by 
methylation subtypes did not differ with respect to established prognostic factors, 
including age (P=0.44), KPS (P=0.80), steroid intake at study entry (P=0.41) or 
MGMT promoter methylation (P=0.91) and no differences in PFS or OS were 
detected (Figure S4). 
Longer PFS in arm A than in arm B was detected solely in the subgroup of RTK I 
glioblastomas (HR 0.25, 95% CI 0.07-0.82, P=0.014, Figures 2B, S3 and S4) and 
there was a trend towards a higher rate of radiographic complete responses of RTK I 
compared to RTK II or MES glioblastomas (Table S4). No gene methylation subtype 
with prolonged OS in arm A versus arm B was identified (Figures 2C, S3 and S4). 
There was an association of methylation subtypes with gene expression subtypes 
(P=0.011), including RTK I methylation in 57% of PN, RTK II methylation in 73% of 
CL and MES methylation in 53% of glioblastomas with MES gene expression (Figure 
2A). No differences in PFS and OS were detected between gene expression 
subtypes (Figure S5). PFS was specifically longer among bevacizumab-treated 
patients with IDH wildtype PN glioblastomas (HR 0.29, 95% CI 0.08-0.98, P=0.025) 
(Figures 2D, S3 and S5). No gene expression subtype with differences in OS 
between treatment arms was identified (Figures 2E, S3 and S5). Outcome analyses 
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of the MES gene expression subtype were precluded by imbalance between 
treatment arms (Table 1, Figure S5). 
 
Multivariate modeling of outcome 
Cox proportional hazards modeling for PFS revealed treatment with bevacizumab 
and higher KPS as relevant prognostic factors, whereas no role for age, steroid 
intake at study entry or MGMT promoter methylation emerged (Table 2). Applying the 
same model to OS revealed age and KPS as relevant prognostic factors (Table 2). 
Univariate analyses are summarized in Table S5. Inclusion of gene methylation and 
gene expression subtypes into this model as additional single variables identified an 
association of the RTK II subtype with inferior PFS and OS (Table S6). 
We also considered the possibility that second line treatment masked effects from 
study treatment on OS. However, in our model the inclusion of any salvage therapy 
versus best supportive care at recurrence did not render treatment arm a prognostic 
factor (HR 1.01, 95% CI 0.55-1.87, P=0.96), and neither were surgery at recurrence 
(HR for arm A versus arm B 0.89, 95% CI 0.34-2.30, P=0.80), or cross-over to 
receive bevacizumab at recurrence in arm B (HR for arm A versus arm B 0.63, 95% 
CI 0.29-1.32, P=0.22) prognostic. In arm B, 13 patients (52%) received bevacizumab 
at first or second recurrence, including two patients (8%) who received bevacizumab 
at first and second recurrence (Figure S1). 
 
 
Discussion 
 
The ARTE trial was designed to provide evidence for a benefit from first-line 
bevacizumab anti-angiogenic therapy when added to RT in elderly glioblastoma 
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patients considered non-eligible for combined modality treatment, based on 
standards of care when the trial was initiated [11]. The amendment of the trial to 
include only patients with an unmethylated MGMT promoter was motivated ethically 
when it became clear that temozolomide and not RT was the preferred first-line 
monotherapy for elderly glioblastoma patients with a methylated MGMT promoter 
considered non-eligible for combined modality treatment [5, 6]. Given that benefit 
from RT is not associated with absence or presence of MGMT promoter methylation 
in this patient population, we focused our analyses on the intention-to-treat 
population.  
We found indeed a small increase in OS of approximately 2 months over the 
historical benchmark of the NOA-08 trial, but a similar increase was also seen in the 
patients treated with RT alone, suggesting an effect of patient selection or improved 
standards of care with time [12], although cross-over to receive bevacizumab in arm 
B contributing to OS cannot be ruled out. Overall the outcome data reported in ARTE 
compare well with contemporary patient populations (Table S7). That the addition of 
bevacizumab increased PFS, but apparently not OS is consistent with the phase III 
trials concluded while ARTE was ongoing [8, 9]. The benefit in PFS with 
bevacizumab according to central review was consistent with the benefit according to 
investigator assessment, albeit the timepoint of progression was antedated in 22% of 
patients in arm A due to more rigorous application of imaging criteria. 
Early uncontrolled reports of bevacizumab therapy in glioblastoma patients 
suggested that benefit may be pronounced in elderly and frail patients [13-15]. 
Accordingly, an OS benefit from bevacizumab in patients who did not qualify for 
second line therapy was reported from secondary analyses of the AVAGlio trial [16]. 
We also noted a tendency towards prolonged OS in patients with lower KPS and in 
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patients who did not receive further treatment at tumor progression, albeit these 
subgroup analyses suffer from the lack of statistical power.  
In line with reports from the AVAGlio trial [8, 17], patient-reported quality of life was 
maintained under bevacizumab at least until progression and more patients came off 
steroids with bevacizumab. In contrast, an association of bevacizumab treatment with 
inferior QoL and worse cognitive functioning was reported from the RTOG-0825 trial 
[9], fostering speculation on putative neurotoxicity of bevacizumab. In the ARTE trial, 
bevacizumab was overall well tolerated, but indeed more neuropsychiatric adverse 
events and cognitive decline prior to progression were noted in arm A. Although 
neurotoxicity from bevacizumab cannot be ruled out, other causes potentially 
contributing to cognitive impairment in individual patients in arm A included the 
prolonged treatment period, imbalances in cognitive functioning at baseline and 
unrecognized tumor progression, as determined by the post-hoc radiology review. 
The largest fraction of adverse events in both treatment arms were classified as other 
neurologic events, comprising mostly sensorimotor symptoms likely related to tumor 
burden.  
Secondary analyses of outcome measures also included stratification by molecular 
markers. Genome-wide analysis of gene methylation identified an association of the 
RTK I methylation subtype and the proneural gene expression subtype with PFS 
benefit from bevacizumab. Although sample size was small, these results confirm the 
previously reported link of preferential benefit from bevacizumab in patients with 
tumors with proneural gene expression pattern [18]. This may provide an important 
path forward for patient selection in future clinical trials exploring VEGF-targeted 
therapies. 
In conclusion, ARTE did not confirm the hypothesis that the combination of 
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bevacizumab with hypofractionated RT prolongs OS in elderly glioblastoma patients, 
but exploratory analyses yielded novel molecular genetic and imaging biomarkers 
that may help to enrich patient populations for future trials on novel anti-VEGF 
compounds. 
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Figure Legends  
 
Figure 1. Clinical outcome by treatment arm. A, B: Progression-free survival (A) 
and overall survival (B) were analyzed in the intention-to-treat population in patients 
treated with bevacizumab and radiotherapy (arm A) versus radiotherapy alone (arm 
B) utilizing the log-rank test. C: Deterioration-free survival in the intention-to-treat 
population in arm A versus arm B. D: Individual functional and symptom scores from 
EORTC QLQ-C30/BN20 modules prior to tumor progression were analyzed in a 
generalized linear mixed model that controlled for time treatment interactions. 
Percent effects and 95% confidence intervals are depicted. E: Cognitive functioning 
prior to tumor progression was assessed by mini-mental status examination (MMSE). 
Boxes define the median and interquartile range, whiskers define the range. 
Differences in treatment arms were compared by Student’s t-test for each timepoint 
using the Holm-Sidak method to correct for multiple comparisons. 
 
Figure 2. Molecular glioblastoma subtypes. A: Unsupervised hierarchical 
clustering by gene methylation patterns. Columns represent patients and rows CpG 
probes. Pearson’s correlation was performed as distance measure and average 
linkage utilizing the 5,000 probes with highest standard deviations. B-E: Progression-
free survival (B, D) and overall survival (C, E) by treatment arm in patients with RTK I 
gene methylation (B, C), and in patients with PN gene expression (D, E) glioblastoma 
subtypes. One patient with IDH mutated glioblastoma was excluded from outcome 
analysis in panels C and E.  
 
Figure S1. CONSORT chart. Abbreviations: BEV, bevacizumab; RT, radiotherapy; 
MGMT, O6-methylguanine DNA methyltransferase; PD, progressive disease. 
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Figure S2. CONSORT chart of MGMT unmethylated patients. Abbreviations: BEV, 
bevacizumab; RT, radiotherapy; PD, progressive disease. 
 
Figure S3. Subgroup analyses of clinical outcomes by treatment arm. Forest plot 
depicting univariate hazard ratios and 95% confidence intervals for progression-free 
survival (left panel) and overall survival (right panel) in arm A versus arm B.  
 
Figure S4. Clinical outcome by gene methylation subtype. A, B: Progression-free 
survival (A) and overall survival (B) were analyzed in patients with receptor tyrosine 
kinase (RTK) I versus RTK II versus mesenchymal (MES) glioblastoma gene 
methylation subtypes. C-F: Progression-free survival (C,E) and overall survival (D,F) 
were analyzed in patients treated with bevacizumab and radiotherapy (arm A) versus 
radiotherapy alone (arm B) in subgroups with RTK II (C, D) and MES (E,F) gene 
methylation. Survival was compared utilizing the log-rank test. The one patient with 
mutated IDH and an IDH mutation-associated gene methylation pattern was the only 
patient who survived without progression for >3 years and who was alive and on 
study treatment at databank closure. 
 
Figure S5. Clinical outcome by gene expression subtype. A, B: Progression-free 
survival (A) and overall survival (B) were analyzed in patients with proneural (PN) 
versus classical (CL) versus mesenchymal (MES) glioblastoma gene expression 
subtypes. C-F: Progression-free survival (C,E) and overall survival (D,F) were 
analyzed in patients treated with bevacizumab and radiotherapy (arm A) versus 
radiotherapy alone (arm B) in subgroups with CL (C, D) and MES (E,F) gene 
expression. Survival was compared utilizing the log-rank test. 


 Table 1. Patient characteristics. 
 Arm A 
N=50 
Arm B 
N=25 
P 
Age at diagnosis (years)    
  Median 70 70  
  Range 65-87 65-79 0.93 
Gender, N (%)    
  Male 32 (64) 16 (64)  
  Female 18 (36) 9 (36) 1.00 
KPS at study entry, N (%)    
  90-100 25 (50) 16 (64)  
  70-80 
  60 
21 (42) 
4 (8) 
6 (24) 
3 (12) 
 
0.30 
MMSE at study entry (points) 
> 27 
< 27 
 
26 (52) 
19 (38) 
 
17 (68) 
3 (12) 
 
 
0.032 
No data 5 (10) 5 (20)  
Steroids at study entry, N (%) 
  Yes 
  No   
 
22 (44) 
27 (54) 
 
12 (44) 
13 (56) 
 
 
0.80 
  No data 1 (2) 0 (0)  
CE-T1 (cm2) 
  Median 
  Range 
 
5.9 
0.0-32.2 
 
3.8 
0.5-17.8 
 
 
0.12 
Tumor burden on T2 (cm2) 
  Median 
  Range 
 
15.3 
2.3-43.2 
 
12.1 
1.8-39.0 
 
 
0.13 
Central histopathology, N (%) 
  Glioblastoma 
  Anaplastic astrocytoma 
  Anaplastic ependymoma 
 
46 (92) 
1 (2) 
0 (0) 
 
23 (96) 
0 (0) 
1 (4) 
 
 
 
1.00 
  No data 3 (6) 1 (4)  
IDH, N (%) 
  Mutated 
  Wildtype 
 
1 (2) 
39 (78) 
 
0 (0) 
19 (76) 
 
 
1.00 
  No data 10 (20) 6 (24)  
MGMT promoter, N (%) 
  Methylated 
  Unmethylated 
 
10 (20) 
37 (74) 
 
6 (24) 
18 (72) 
 
 
0.72 
  No data 3 (6) 1 (4)  
Gene methylation, N (%)1 
  RTK I 
  RTK II 
  MES 
  MYCN 
  IDH mut 
 
11 (22) 
15 (30) 
11 (22) 
1 (2) 
1 (2) 
 
5 (20) 
8 (32) 
5 (20) 
0 (0.0) 
0 (0.0) 
 
0.67 
0.73 
0.88 
n.a. 
n.a. 
  No data 11 (22) 7 (28) n.a. 
Gene expression, N (%)2 
  PN 
  CL  
 
9 (18) 
11 (22) 
 
6 (24) 
8 (32) 
 
0.39 
0.20 
   MES 15 (30) 2 (8) 0.033 
  No data 15 (30) 9 (36) n.a. 
 
Abbreviations: CE-T1, contrast enhancement on T1-weighted images; CI, confidence 
interval; CL, classical; IDH, isocitrate dehydrogenase; KPS, Karnofsky performance 
score; MMSE, mini-mental status examination; MES, mesenchymal; MGMT, O6-
methylguanine DNA methyltransferase; MYCN, N-myc proto-oncogene; PN, 
proneural; RTK, receptor tyrosine kinase; 1 Jones et al. 2014 ; 2 Verhaak et al. 2010   
Table 2. Multivariate analyses of associations with PFS and OS.  
 PFS OS 
 Hazard ratio 
and 95% CI  
P Hazard ratio 
and 95% CI  
P 
Treatment arm:  
arm A versus arm B  
0.36 (0.20-0.65) 0.001 1.09 (0.63-1.89) 0.75 
Age at study entry:  
65-69 versus 70+ years 
1.13 (0.66-1.92) 0.651 0.52 (0.30-0.89) 0.018 
KPS:  
90-100% versus 60-80% 
0.50 (0.28-0.89) 0.018 0.51 (0.28-0.92) 0.026 
Steroids at study entry:  
no versus yes 
1.10 (0.66-1.84) 0.704 0.87 (0.52-1.44) 0.59 
MGMT promoter: methylated 
versus unmethylated* 
0.69 (0.37-1.30) 0.250 0.79 (0.42-1.49) 0.46 
 
* note that enrollment was restricted per amendment 1 to unmethylated patients (see 
Figure S2) 
 
